Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial

BMC Complementary and Alternative Medicine

Research Article

Ralf Schubert¹  Johannes Schulze¹  Stefan Zielen¹  Markus A Rose¹  Bianca Weigand¹ 

[1] Dpt. of Allergy, Pulmonology, and Cystic Fibrosis, Children's and Adolescents' Hospital, Goethe University, Theodor Stern Kai 7, 60590, Frankfurt, Germany;

关键词: autovaccine;    safety;    tolerability;    house dust mite allergy;    asthma;   

DOI  :  10.1186/1472-6882-11-45

 received in 2010-06-23, accepted in 2011-06-03,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundAsthma is increasing worldwide and results from a complex immunological interaction between genetic susceptibility and environmental factors. Autovaccination with E. coli induces a strong TH-1 immune response, thus offering an option for the treatment of allergic diseases.MethodsProspective open trial on safety, tolerability, and impact on allergic inflammation of an autologous E.coli autovaccine in intermittent or mild persistent house dust mite asthma. Determination of exhaled nitric monoxide (eNO) before and after bronchial mite challenge initially and after nine months of autovaccination.ResultsIn nine subjects and a total of 306 injections, we observed 101 episodes of local erythema (33.3%; median of maximal diameter 2.5 cm), 95 episodes of local swelling (31.1%; median of maximal diameter 3 cm), and 27 episodes of local pain (8.8%). Four subjects reported itching at the injection site with a total of 30 episodes (9.8%). Median eNO increase after autovaccination was significantly smaller (from 27.3 to 33.8 ppb; p = 0.334) compared to initial values (from 32.6 to 42.2 ppb; p = 0.046) (p = 0.034). We observed no serious adverse events. All organ functions (inclusive electrocardiogramm) and laboratory testing of the blood (clinical chemistry, hematology) and the urine (screening test, Β-microglobuline) were within normal limits. Vital signs undulated within the physiological variability.ConclusionThe administration of autologous autovacine for the treatment of house dust mite asthma resulted in a reduction of the eNO increase upon bronchial mite challenge. In nine subjects and 306 injections, only a few mild local reactions and no systemic severe adverse events were observed.Trial registrationEudraCT Nr. 2005-005534-12ClinicalTrials.gov IDNCT00677209

【 授权许可】

CC BY   
© Rose et al; licensee BioMed Central Ltd. 2011